Current issues in GLP-1 receptor agonist therapy for type 2 diabetes

Endocr Pract. Nov-Dec 2012;18 Suppl 3:6-26; quiz 27-8. doi: 10.4158/EP12300.RA.

Abstract

The clinical management of hyperglycemia in patients with type 2 diabetes mellitus (T2DM) is guided not only by published treatment algorithms, but also by consideration of recent evidence and through consultation with colleagues and experts. Recent studies have dramatically increased the amount of information regarding the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Topics that may be of particular interest to clinicians who treat T2DM patients include relative glycemic control efficacy of GLP-1 RAs, use of GLP-1 RAs across T2DM progression and in combination with insulin, recent data regarding GLP-1 RA safety, nonglycemic actions of GLP-1 RAs, including weight effects, and impact of GLP-1 RAs on patient quality of life and treatment satisfaction. The following review includes expert consideration of these topics with emphasis on recent, relevant reports to illustrate current perspectives.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Glucagon-Like Peptide 1 / agonists*
  • Humans
  • Hypoglycemic Agents / therapeutic use

Substances

  • Hypoglycemic Agents
  • Glucagon-Like Peptide 1